Navigation Links
Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
Date:2/9/2011

FRAZER, Pa., Feb. 9, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) and Alba Therapeutics Corporation, a privately held biopharmaceutical company, today announced that the companies have signed an agreement providing Cephalon with an option to purchase all of Alba's assets relating to larazotide acetate, a tight junction modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease. Under the terms of the option agreement, Cephalon will pay Alba a $7 million upfront option payment and will provide a credit facility to fund Alba's Phase IIb clinical trial expenses for larazotide acetate.

Cephalon may exercise its option at any time prior to the expiration of a specified period after receipt of the final study report for the Phase IIb clinical trial. If Cephalon exercises its option, the company will purchase Alba's assets for $15 million.  Alba could receive additional payments related to regulatory and sales milestones.

"We are encouraged by the data that we have evaluated," said Kevin Buchi, Cephalon's CEO. "Alba will now initiate a Phase IIb trial utilizing a more disease specific primary endpoint.  If successful, larazotide acetate will add to our pipeline in immunology and has the potential to be the first pharmacologic therapy available to treat patients who endure this often serious condition."

"Celiac disease affects approximately three million people in the US and 15 million worldwide.  For the past six years Alba has been working diligently to research and develop larazotide acetate, a new oral peptide that has been tested in approximately 450 patients with celiac disease.  We are excited to work with our partner Cephalon.  Their passion and experience goes hand in hand with bringing new medicines to the market for patients who suffer from this disease," said Wendy Perrow, President and COO of
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
2. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
3. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
4. Cephalon to Webcast Investor Day
5. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
6. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
7. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
8. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
9. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
10. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
11. Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... The western European automated endoscope reprocessor ... a replacement market with fewer new installations due ... partnerships are redefining competitive landscape in western ... details about revenue forecasts, unit shipments, market share ... country. The changing landscape makes it important to ...
(Date:9/22/2014)... -- Research and Markets  has announced the addition ... report to their offering. This newly ... up-to-date publication available covering the neurotechnology industry. The report ... and growth rates in four key segments of the ... forecasts the number of systems to be sold, worldwide ...
(Date:9/22/2014)... , Sept. 22, 2014 Children,s National ... Monday, Sept. 29 at 5 p.m. EDT for ... competition, in response to continued strong interest from ... each will be awarded to the winning presentations ... Innovation Symposium hosted by Children,s National in October. ...
Breaking Medicine Technology:Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3The Market for Neurotechnology: 2014-2018 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3
... , Increased vaccination ... gaps remain, others must join effort , DAVOS, Switzerland ... announced today that their foundation will commit $10 billion ... deliver vaccines for the world,s poorest countries. , (Photo: ...
... , , REDWOOD CITY, Calif. ... today announced financial results for its fiscal second quarter and six months ... call at 4:30 p.m. Eastern Time to discuss the financial ... quarter, as we continued to transition the sales model for our cardiac ...
Cached Medicine Technology:Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 2Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 3Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 4Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 5Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 6Cardica Announces Fiscal 2010 Second Quarter Financial Results 2Cardica Announces Fiscal 2010 Second Quarter Financial Results 3Cardica Announces Fiscal 2010 Second Quarter Financial Results 4Cardica Announces Fiscal 2010 Second Quarter Financial Results 5Cardica Announces Fiscal 2010 Second Quarter Financial Results 6Cardica Announces Fiscal 2010 Second Quarter Financial Results 7Cardica Announces Fiscal 2010 Second Quarter Financial Results 8Cardica Announces Fiscal 2010 Second Quarter Financial Results 9
(Date:9/23/2014)... Sandpoint, Idaho (PRWEB) September 23, 2014 ... GunSafes.com is now offering SecureIt Tactical products ... prices. SecureIt Tactical, Inc. holds a good name in ... The company stores only the finest products and now ... tactical gun safes such as the MilSpec Tactical Safe ...
(Date:9/22/2014)... Vida Cannabis Corp . is ... Agreement with Florida-based AltMed LLC . , ... and technical expertise. They’ll also pool business development ... markets. , "We’re deeply impressed with the level ... Cannabis team as they work toward building the most ...
(Date:9/22/2014)... Detroit MI (PRWEB) September 23, 2014 ... 3 organization dedicated to serving patients, caregivers and families ... of Philip M. Fortier of Detroit, MI to its ... disease of the brain and spinal cord, and is ... addition to resembling Parkinson’s disease (MSA Type P), MSA ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Airbus Helicopters ... industry Monday for their efforts to improve safety and ... Award and the Program of the Year award, both ... Air Medical Transport Conference Annual Community Awards. , ... with the Jim Charlson Aviation Safety Award, given annually ...
(Date:9/22/2014)... United States District Judge Joseph ... mesh lawsuits ( http://www.meshinjurylawfirm.com/lawsuits/ ) filed against defendant ... pretrial matters, issued an order in the multidistrict ... Products Liability Litigation (United States District Court for ... 2:12-md-02326)—requiring that four member cases be ready for ...
Breaking Medicine News(10 mins):Health News:GunSafes.com Now Offers Secure Tactical Range of Gun Safes 2Health News:Vida Cannabis Allies with Florida Medical Cannabis Leader AltMed to Build Best-in-Class Expertise 2Health News:Philip Fortier appointed to Multiple System Atrophy Coalition Board of Directors 2Health News:Philip Fortier appointed to Multiple System Atrophy Coalition Board of Directors 3Health News:Airbus Helicopters Inc. Honors Leaders in Air Medical Industry 2Health News:Airbus Helicopters Inc. Honors Leaders in Air Medical Industry 3Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2
... U.S. Environmental,Protection Agency has given $97,204 to ... providers and women of child-bearing age on,environmental health ... grants nationwide. In Ohio, the grant will be ... woman,s potential exposure to environmental,risks., The EPA ...
... N.J., Feb. 4 NPS Pharmaceuticals,Inc. (Nasdaq: NPSP ... and chief operating officer, is scheduled to present at ... York on Monday, February,11, 2008 at 1:15 p.m. ET. ... a replay available approximately three hours after the,presentation has ...
... MONDAY, Feb. 4 (HealthDay News) -- Drug-coated stents are better ... research finds. , "There are two messages I would take ... professor of cardiology at Wake Forest University and lead author ... Journal of the American College of Cardiology. "The ...
... has,agreed to settle for $2.5 million, plus interest, ... program, the Justice Department,announced today. The settlement is ... Medical Center is currently in bankruptcy., The ... to Medicare patients in order to obtain enhanced,reimbursement ...
... ALTO, Calif., Feb. 4 Formerly conjoined twins,Yurelia ... at Stanford and are now home in Costa ... Children,s last Wednesday (30) and went,to Southern California ... sponsor the girls, trip. Today (4), they flew ...
... Those with poor balance, dementia, vision loss most in peril, ... -- Certain people are at high risk for accidental falls ... number of fall-related injuries and deaths in the United States, ... States, accidental falls result in 1.8 million emergency room visits ...
Cached Medicine News:Health News:Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases 2Health News:Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases 3Health News:Buyer of Bayonne Hospital to Pay U.S. $2.5 Million to Resolve Allegations of Medicare Fraud 2Health News:Formerly Conjoined Twins Leave Packard Children's Hospital; Heading Home to Costa Rica 2Health News:New Guideline Urges Screening for Fall Risk 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: